 |
|
|
Paloma Pharmaceuticals has created a library of proprietary non-steroidal small molecule drugs through three generations of de novo computational design, medicinal chemistry and synthesis resulting in first-in-class PI3K/Akt/mTOR inhibition through dissociation of the TORC1 and TORC2 protein complexes. Of the 3rd generation analogs tested showing significantly greater activity over previous generations. Palomid 529 was chosen as the candidate molecule for clinical development due to performance in a variety of in vitro and in vivo animal models.
|
|
| | |
|
|
|
